Sep 12, 2022
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Sep 05, 2022
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Aug 29, 2022
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Jul 31, 2022
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC
Jul 28, 2022
Immutep Quarterly Activities Report
